Real World Evidence (RWE) Providers Market for Pharmaceutical Companies in Europe and in the US

CHALLENGE

Our client, a European Private Equity, sought a comprehensive understanding of how Real World Evidence (RWE) impacts drug development, clinical trials, and regulatory approvals. The focus was on evaluating the necessity of RWE for accelerating these processes, assessing the market size and growth for RWE services, and understanding the role of in-house versus third-party providers. Key questions included the need for RWE, its market dynamics, and the criteria for selecting RWE service providers.

OUR APPROACH

To address these needs, BTHT provided the client with top experts in the RWE field. Our portfolio of experts for this project included roles such as: - Global Market Access and Health Economy - Clinical Trial Manager - Executive Director, Head Medical Affairs Europe

Key Questions Explored:

1. The importance of RWE.
2. The market size for RWE services in pharma.
3. In-house RWE services or third-party providers?
4. RWE providers.

BTHT actively scheduled and participated in the consultation in order to ensure smooth communication between the client and the experts, and to maintain confidentiality.

OUTCOME

BTHT's experts provided valuable insights into the role of RWE in drug development, market dynamics, and provider selection criteria. Our experts' expertise helped the client understand the necessity and impact of RWE, as well as the competitive landscape of RWE service providers.